Patents by Inventor Sharmistha ACHARYA

Sharmistha ACHARYA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTIBODY TREATMENT OF LYMPHOID MALIGNANT NEOPLASM CONDITIONS
    Publication number: 20230365681
    Abstract: Provided is a method for the treatment of a lymphoid malignant neoplasm in a subject in need thereof comprising administering to the subject an effective amount of a bispecific antibody which comprises a Fab portion that binds CD47 and a Fab portion that binds CD20. In some embodiments, the lymphoid malignant neoplasm is Non-Hodgkin's Lymphoma (NHL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or primary mediastinal B-cell lymphoma. In certain embodiments, the lymphoid malignant neoplasm is NHL.
    Type: Application
    Filed: October 5, 2021
    Publication date: November 16, 2023
    Inventors: Haralambos HADJIVASSILIOU, Dan ZHU, Jeonghoon SUN, Sharmistha ACHARYA, Jeffrey JOHNSON, Kandasamy HARIHARAN, Ho CHO
  • ENGINEERING OF AN ANTIBODY FOR TUMOR-SELECTIVE BINDING OF CD47
    Publication number: 20220340675
    Abstract: Antibodies are provided which comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor associated antigen (TAA) CD20; wherein the Fab portion that binds CD47 exhibits low affinity for CD47; and, wherein the Fab portion that binds CD20 exhibits high affinity for CD20; and, wherein the antibody selectively binds CD47 and blocks CD47 interaction with SIRP? in tumor cells while exhibiting no substantial binding to CD47 in normal cells.
    Type: Application
    Filed: April 3, 2020
    Publication date: October 27, 2022
    Inventors: Haralambos HADJIVASSILIOU, Dan ZHU, Jeonghoon SUN, Sharmistha ACHARYA, Jeffrey JOHNSON, Henry CHAN, Kandasamy HARIHARAN, Ho CHO
  • ENGINEERING OF AN ANTIBODY FOR TUMOR-SELECTIVE BINDING OF CD47
    Publication number: 20220162330
    Abstract: Antibodies are provided which comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor associated antigen (TAA) CD20; wherein the Fab portion that binds CD47 exhibits low affinity for CD47; and, wherein the Fab portion that binds CD20 exhibits high affinity for CD20; and, wherein the antibody selectively binds CD47 and blocks CD47 interaction with SIRP? in tumor cells while exhibiting no substantial binding to CD47 in normal cells.
    Type: Application
    Filed: April 3, 2020
    Publication date: May 26, 2022
    Inventors: Haralambos HADJIVASSILIOU, Dan ZHU, Jeonghoon SUN, Sharmistha ACHARYA, Jeffrey JOHNSON, Kandasamy HARIHARAN, Ho CHO